Abacavir/dolutegravir/lamivudine is a fixed-dose combination containing two nucleoside reverse transcriptase inhibitors (NRTIs) and integrase strand transfer inhibitor (INSTI).
The FDA has granted tentative approval for Viatris’ abacavir/dolutegravir/lamivudine for oral suspension to treat HIV-1 infection in children. It is the generic of ViiV Healthcare’s Triumeq PD, which the FDA approved in March 2022.1
The tentative approval is through the President’s Emergency Plan for AIDS Relief (PEPFAR) program. Viatris has signed a licensing agreement for pediatric dolutegravir from the Medicines Patent Pool and development agreement with ViiV Healthcare and the Clinton Health Access Initiative for producing and distributing the fixed-dose combination of abacavir/ dolutegravir/lamivudine. The tentative approval eases regulatory authority submissions, production and distribution across 123 low- and middle-income countries.
The World Health Organization recommends abacavir/dolutegravir/lamivudine as a preferred first-line regimen for pediatric patients. According to the Joint United Nations Program on HIV/AIDS, about 660,000 children living with HIV, which works to about approximately 4\0% of the estimated total 1.5 million children living with HIV , did not receive antiretroviral (ARV) therapy in 2022.
“The approval of this single tablet regimen – the fixed-dose combination of abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg — will reduce the pill burden for children living with HIV,” Rakesh Bamzai, president of India, Emerging Asia & Access Markets at Viatris, said in a press release.
Abacavir/dolutegravir/lamivudine is a fixed-dose combination containing two nucleoside reverse transcriptase inhibitors (NRTIs) and integrase strand transfer inhibitor (INSTI). NRTIs interfere with the action of the reverse transcriptase enzyme and INSTI interferes with the action of integrase enzyme to prevent the virus from replicating.